Sign in

CIK 0001662774

  • Non-accelerated filer
  • Smaller reporting company

IRulya Therapeutics Inc.

Sign in to watch
Ticker
IRLA
Exchange
Nasdaq
Industry
Biological Products, (No Diagnostic Substances)
FY end
Dec 31
Incorporated
DE
Entity type
Operating
EIN
901024039
Phone
+1 203-208-8994
Business address
101 COLLEGE STREET, SUITE 210, NEW HAVEN, CT, 06510
Former names
Quince Therapeutics, Inc., Cortexyme, Inc.
  1. 4 Derivatives Options or other derivatives
  2. 4 Open-market sale Chief Accounting Officer & VP sold 1,871 shares at $0.98 ($1,834)
  3. 4 Derivatives Options or other derivatives
  4. 4 Derivatives Options or other derivatives
  5. 4 Derivatives Options or other derivatives
  6. 4 Derivatives Options or other derivatives
  7. 4 Shares withheld for taxes Chief Accounting Officer & VP gave up 1,640 shares (to pay taxes)
  8. 4 Shares withheld for taxes Chief Accounting Officer & VP gave up 1,520 shares (to pay taxes)
  9. 4 Derivatives Options or other derivatives
  10. 4 Derivatives Options or other derivatives
  11. 3 Insider Initial Statement of Ownership
  12. 4 Derivatives Options or other derivatives
  13. 4 Derivatives Options or other derivatives
  14. 4 Derivatives Options or other derivatives
  15. 4 Derivatives Options or other derivatives
  16. 4 Shares withheld for taxes Chief Accounting Officer & VP gave up 1,529 shares (to pay taxes)
  17. 4 Shares withheld for taxes EVP, Preclinical Development gave up 10,920 shares (to pay taxes)
  18. 4 Open-market sale Chief Legal & Adm. Officer sold 10,800 shares at $2.86 ($30,923)
  19. 4/A Grant or award Chief Medical Officer acquired 170,354 shares (grant or award)
  20. 4/A Grant or award Chief Executive Officer acquired 216,322 shares (grant or award)

Page 5 of 11 · 211 filings